抗RNPC-3抗体预测系统性硬化症相关间质性肺病不良预后
基于巴塞罗那与米兰共447例系统性硬化症患者的队列,采用颗粒多分析技术检测抗RNPC-3抗体,比较阳性与阴性患者的临床特征及生存。抗RNPC-3阳性者间质性肺病更常见,终末期肺病或死亡风险更高,无事件生存期更短,提示该抗体是独立的不良预后标志,尤其合并间质性肺病时。
要点
- 抗RNPC-3抗体在系统性硬化症中阳性率4.3%,与间质性肺病风险升高相关。
- 抗RNPC-3阳性者终末期肺病或死亡风险更高,无事件生存期更短。
- 多因素分析显示抗RNPC-3是独立的不良预后抗体,合并间质性肺病时尤著。
核心结论
- 抗RNPC-3抗体与系统性硬化症患者间质性肺病及终末期肺病或死亡风险升高相关,是独立的不良预后抗体。
研究设计与样本
- 多中心队列研究,纳入巴塞罗那286例与米兰161例共447例系统性硬化症患者,用颗粒多分析技术检测抗体并比较抗RNPC-3阳性与阴性者。
主要发现
- 抗RNPC-3阳性组间质性肺病比例更高(57.9% vs 33.6%,P=0.030)。
- 抗RNPC-3阳性组终末期肺病比例更高(36.8% vs 17.3%,P=0.006)。
- 抗RNPC-3阳性组非糖皮质激素免疫抑制剂使用更多(57.9% vs 30.4%,P=0.012)。
- 抗RNPC-3阳性者无事件生存期更短,总队列log-rank P=0.001,间质性肺病患者中log-rank P=0.002。
关键数值与推荐
- 终末期肺病定义为用力肺活量低于预计值50%、需氧疗或肺移植。
- 无事件生存期定义为无终末期肺病或死亡的生存时间。
- 多因素Cox回归中,弥漫皮肤亚型、发病年龄、间质性肺病或肺动脉高压、抗RNPC-3或抗拓扑异构酶I阳性与更差无事件生存独立相关。
临床怎么用
- 对系统性硬化症患者检测抗RNPC-3抗体有助于识别间质性肺病及不良预后高危人群。
- 抗RNPC-3阳性尤其合并间质性肺病者应加强肺功能监测与病情评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyse the prevalence, the clinical characteristics, the overall survival and the event-free survival (EFS) of SSc patients who express anti-U11/U12 RNP (RNPC-3) antibodies. METHODS: A total of 447 SSc patients from Barcelona (n = 286) and Milan (n = 161) were selected. All samples were tested using a particle-based multi-analyte technology. We compared anti-RNPC-3 positive and negative patients. Epidemiological, clinical features and survival were analysed. End-stage lung disease (ESLD) was defined if the patient developed forced vital capacity <50% of predicted, needed oxygen therapy or lung transplantation. EFS was defined as the period of time free of either ESLD or death. RESULTS: Nineteen of 447 (4.3%) patients had anti-RNPC-3 antibodies and interstitial lung disease (ILD) was more frequent (11, 57.9% vs 144, 33.6%, P =0.030) in individuals with anti-RNPC-3 antibodies. More patients reached ESLD in the positive group (7, 36.8% vs 74, 17.3%, P = 0.006), and a higher use of non-glucocorticoid immunosuppressive drugs was observed (11, 57.9% vs 130, 30.4%, P = 0.012). Anti-RNPC-3 positive patients had lower EFS, both in the total cohort (log-rank P =0.001), as well as in patients with ILD (log-rank P = 0.002). In multivariate Cox regression analysis, diffuse cutaneous subtype, age at onset, the presence of ILD or pulmonary arterial hypertension and the expression of anti-RNPC-3 positivity or anti-topo I were independently associated with worse EFS. CONCLUSION: The presence of anti-RNPC-3 was associated with higher frequency of ILD and either ESLD or death. These data suggest anti-RNPC-3 is an independent poor prognosis antibody in SSc, especially if ILD is also present.
引用
- Callejas-Moraga EL, Guillén-Del-Castillo A, Perurena-Prieto J, et al. Anti-RNPC-3 antibody predicts poor prognosis in patients with interstitial lung disease associated to systemic sclerosis. Rheumatology (Oxford). 2021. PMID: 33742673. doi:10.1093/rheumatology/keab279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。